Education
About Us
Working with TipRanks
Follow Us
Sionna Therapeutics, Inc. (SION)
NASDAQ:SION
Top Page
Sionna Therapeutics, Inc.
(NASDAQ:SION)
Select Model
Select Model
Rating:47Neutral
Price Target:
$39.00
▼(-9.74% Downside)
The score is primarily constrained by weak financial performance—no revenue, widening losses, rising cash burn, and deeply negative equity—implying elevated financing risk. Technicals are mixed but currently soft (below key short-term averages with weak momentum), while valuation is also pressured by ongoing unprofitability and lack of dividend support.
Sionna Therapeutics, Inc. (SION) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.66B
Dividend YieldN/A
Average Volume (3M)311.13K
Price to Earnings (P/E)―
Beta (1Y)1.07
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees41
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.46
Shares Outstanding44,628,788
10 Day Avg. Volume419,975
30 Day Avg. Volume311,134
Financial Highlights & Ratios
PEG Ratio-0.59
Price to Book (P/B)-6.74
Price to Sales (P/S)0.00
P/FCF Ratio-20.89
Enterprise Value/Market Cap0.64
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-4.33K
Enterprise Value/Ebitda-14.19
Forecast
1Y Price Target
$47.80Price Target Upside10.62% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
EPS Forecast (FY)-2
Revenue Forecast (FY)N/A
Sionna Therapeutics, Inc. Business Overview & Revenue Model
Company DescriptionSionna Therapeutics, Inc. is a biopharmaceutical company. The Company provides treatment paradigm for cystic fibrosis patients by developing medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator.
How the Company Makes Money
Sionna Therapeutics, Inc. Financial Statement Overview
Summary
Income Statement
Balance Sheet
Cash Flow
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
Income Statement | ||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -247.00K | -668.00K | 0.00 | 0.00 |
| EBITDA | -75.29M | -69.89M | -49.75M | -41.25M |
| Net Income | -70.68M | -61.69M | -47.26M | -40.24M |
Balance Sheet | ||||
| Total Assets | 339.27M | 185.75M | 51.95M | 87.37M |
| Cash, Cash Equivalents and Short-Term Investments | 248.33M | 147.54M | 38.52M | 82.61M |
| Total Debt | 8.97M | 9.75M | 10.48M | 0.00 |
| Total Liabilities | 17.60M | 349.46M | 166.83M | 157.29M |
| Stockholders Equity | 321.67M | -163.71M | -114.88M | -69.92M |
Cash Flow | ||||
| Free Cash Flow | -61.65M | -52.81M | -44.81M | -37.94M |
| Operating Cash Flow | -61.45M | -52.79M | -43.70M | -36.07M |
| Investing Cash Flow | -126.11M | -126.91M | 27.35M | -29.26M |
| Financing Cash Flow | 202.64M | 178.97M | 31.00K | 110.86M |
Sionna Therapeutics, Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | $2.01B | 53.30 | 15.02% | ― | 1128.17% | ― | |
56 Neutral | $1.29B | -9.00 | -29.01% | ― | -27.61% | -69.49% | |
53 Neutral | $1.25B | -6.66 | -56.52% | ― | -100.34% | 52.85% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $1.30B | -12.86 | -51.65% | ― | 53.28% | 21.77% | |
48 Neutral | $829.19M | -1.70 | -49.06% | ― | -78.55% | 7.74% | |
47 Neutral | $1.66B | -27.03 | -28.07% | ― | ― | ― |
* Healthcare Sector Average
SION
Sionna Therapeutics, Inc.
43.21
20.97
94.29%
STOK
Stoke Therapeutics
35.17
26.17
290.78%
VIR
Vir Biotechnology
6.16
-5.94
-49.09%
IMTX
Immatics
9.84
3.41
53.03%
TNGX
Tango Therapeutics
11.79
8.87
303.77%
AMLX
Amylyx Pharmaceuticals Inc
11.99
8.49
242.57%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.